176 related articles for article (PubMed ID: 23435031)
1. Dehydroepiandrosterone sulfate levels reflect endogenous luteinizing hormone production and response to human chorionic gonadotropin challenge in older female macaque (Macaca fascicularis).
Moran FM; Chen J; Gee NA; Lohstroh PN; Lasley BL
Menopause; 2013 Mar; 20(3):329-35. PubMed ID: 23435031
[TBL] [Abstract][Full Text] [Related]
2. Effects of subchronic infusion of dehydroepiandrosterone sulfate on serum gonadotropin levels and ovarian function in the cynomolgus monkey.
Kowalski W; Chatterton RT
Fertil Steril; 1992 Apr; 57(4):912-20. PubMed ID: 1532562
[TBL] [Abstract][Full Text] [Related]
3. Modulation of higher-primate adrenal androgen secretion with estrogen-alone or estrogen-plus-progesterone intervention.
Conley AJ; Stanczyk FZ; Morrison JH; Borowicz P; Benirschke K; Gee NA; Lasley BL
Menopause; 2013 Mar; 20(3):322-8. PubMed ID: 23435030
[TBL] [Abstract][Full Text] [Related]
4. Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction.
Cedars MI; Steingold KA; de Ziegler D; Lapolt PS; Chang RJ; Judd HL
Fertil Steril; 1992 Mar; 57(3):495-500. PubMed ID: 1531463
[TBL] [Abstract][Full Text] [Related]
5. Suppression of luteal function by a luteinizing hormone-releasing hormone antagonist during the early luteal phase in the stumptailed macaque monkey and the effects of subsequent administration of human chorionic gonadotropin.
Fraser HM; Nestor JJ; Vickery BH
Endocrinology; 1987 Aug; 121(2):612-8. PubMed ID: 3109885
[TBL] [Abstract][Full Text] [Related]
6. Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by luteinizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing.
Ibañez L; Hall JE; Potau N; Carrascosa A; Prat N; Taylor AE
J Clin Endocrinol Metab; 1996 Nov; 81(11):4103-7. PubMed ID: 8923867
[TBL] [Abstract][Full Text] [Related]
7. Ovarian and adrenal steroid production: regulatory role of LH/HCG.
Piltonen T; Koivunen R; Morin-Papunen L; Ruokonen A; Huhtaniemi IT; Tapanainen JS
Hum Reprod; 2002 Mar; 17(3):620-4. PubMed ID: 11870113
[TBL] [Abstract][Full Text] [Related]
8. Titrating luteinizing hormone surge requirements for ovulatory changes in primate follicles. I. Oocyte maturation and corpus luteum function.
Zelinski-Wooten MB; Lanzendorf SE; Wolf DP; Chandrasekher YA; Stouffer RL
J Clin Endocrinol Metab; 1991 Sep; 73(3):577-83. PubMed ID: 1908481
[TBL] [Abstract][Full Text] [Related]
9. Ovarian adrenal interactions during the menopausal transition.
Lasley BL; Crawford SL; McConnell DS
Minerva Ginecol; 2013 Dec; 65(6):641-51. PubMed ID: 24346252
[TBL] [Abstract][Full Text] [Related]
10. Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome.
Gonzalez F; Hatala DA; Speroff L
Am J Obstet Gynecol; 1991 Sep; 165(3):535-45. PubMed ID: 1832519
[TBL] [Abstract][Full Text] [Related]
11. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
[TBL] [Abstract][Full Text] [Related]
12. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
13. Titrating luteinizing hormone surge requirements for ovulatory changes in primate follicles. II. Progesterone receptor expression in luteinizing granulosa cells.
Chandrasekher YA; Brenner RM; Molskness TA; Yu Q; Stouffer RL
J Clin Endocrinol Metab; 1991 Sep; 73(3):584-9. PubMed ID: 1908482
[TBL] [Abstract][Full Text] [Related]
14. Effects of gonadotropin-releasing hormone agonist on human chorionic gonadotropin activity in granulosa cells of immature female rats.
Tungmahasuk D; Fungbun N; Laoharatchatathanin T; Terashima R; Kurusu S; Kawaminami M
J Reprod Dev; 2018 Apr; 64(2):129-134. PubMed ID: 29249775
[TBL] [Abstract][Full Text] [Related]
15. Functional luteinizing hormone/chorionic gonadotropin receptors in human adrenal cortical H295R cells.
Rao ChV; Zhou XL; Lei ZM
Biol Reprod; 2004 Aug; 71(2):579-87. PubMed ID: 15084485
[TBL] [Abstract][Full Text] [Related]
16. Effects of a long-acting gonadotropin-releasing hormone analog on the pituitary-ovarian-adrenal axis in women with severe hirsutism.
Castelo-Branco C; Martínez de Osaba MJ; Martínez S; Fortuny A
Metabolism; 1996 Jan; 45(1):24-7. PubMed ID: 8544772
[TBL] [Abstract][Full Text] [Related]
17. Administration of human luteinizing hormone (hLH) to macaques after follicular development: further titration of LH surge requirements for ovulatory changes in primate follicles.
Zelinski-Wooten MB; Hutchison JS; Chandrasekher YA; Wolf DP; Stouffer RL
J Clin Endocrinol Metab; 1992 Aug; 75(2):502-7. PubMed ID: 1639951
[TBL] [Abstract][Full Text] [Related]
18. Effects of dibutyryl adenosine 3',5'-monophosphate, luteinizing hormone-releasing hormone, and aromatase inhibitor on simultaneous outputs of progesterone, 17 beta-estradiol, and human chorionic gonadotropin by term placental explants.
Haning RV; Choi L; Kiggens AJ; Kuzma DL; Summerville JW
J Clin Endocrinol Metab; 1982 Aug; 55(2):213-8. PubMed ID: 6282920
[TBL] [Abstract][Full Text] [Related]
19. The pituitary-gonadal axis in women with benign or malignant ovarian tumors.
Blaakaer J; Djursing H; Hørding U; Bennett P; Toftager-Larsen K; Bock JE; Lebech PE
Acta Endocrinol (Copenh); 1992 Aug; 127(2):127-30. PubMed ID: 1388313
[TBL] [Abstract][Full Text] [Related]
20. Suppression of corpus luteum function by the gonadotropin-releasing hormone antagonist Nal-Glu: effect of the dose and timing of human chorionic gonadotropin administration.
Dubourdieu S; Charbonnel B; Massai MR; Marraoui J; Spitz I; Bouchard P
Fertil Steril; 1991 Sep; 56(3):440-5. PubMed ID: 1894021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
